Sarah E Bohndiek1, Laura S Sasportas1, Steven Machtaler1, Jesse V Jokerst1, Sharon Hori1, Sanjiv S Gambhir2. 1. Bio-X Program and Department of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, California. 2. Bio-X Program and Department of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, California sgambhir@stanford.edu.
Abstract
UNLABELLED: The primary aim of this study was to assess the potential of in vivo photoacoustic tomography for direct functional measurement of ovarian tumor response to antiangiogenic therapy. METHODS: In vivo studies were performed with institutional animal care and use committee approval. We used an orthotopic mouse model of ovarian cancer treated with trebananib (n = 9) or vehicle (n = 9). Tumor-bearing mice were randomized into trebananib or vehicle groups at day 10 and dosed on days 12, 15, and 18 after implantation. Photoacoustic tomography and blood draws were performed at day 10 and then 24 h after each drug dose. Tumors were excised for histopathology after the final studies on day 19. Data analysis to test for statistical significance was performed blinded. RESULTS: Blockade of angiopoietin signaling using trebananib resulted in reduced total hemoglobin-weighted photoacoustic signal (n = 9, P = 0.01) and increased oxyhemoglobin-weighted photoacoustic signal (n = 9, P < 0.01). The latter observation indicated normalization of the residual tumor vessels, which was also implied by low levels of angiopoietin 1 in serum biomarker profiling (0.76 ± 0.12 ng/mL). These noninvasive measures reflected a 30% reduction in microvessel density and increased vessel maturation in ex vivo sections. CONCLUSION: Photoacoustic tomography is able to evaluate both vessel regression and normalization in response to trebananib. Noninvasive imaging data were supported by modulation of serum markers in vitro and ex vivo histopathology.
UNLABELLED: The primary aim of this study was to assess the potential of in vivo photoacoustic tomography for direct functional measurement of ovarian tumor response to antiangiogenic therapy. METHODS: In vivo studies were performed with institutional animal care and use committee approval. We used an orthotopic mouse model of ovarian cancer treated with trebananib (n = 9) or vehicle (n = 9). Tumor-bearing mice were randomized into trebananib or vehicle groups at day 10 and dosed on days 12, 15, and 18 after implantation. Photoacoustic tomography and blood draws were performed at day 10 and then 24 h after each drug dose. Tumors were excised for histopathology after the final studies on day 19. Data analysis to test for statistical significance was performed blinded. RESULTS: Blockade of angiopoietin signaling using trebananib resulted in reduced total hemoglobin-weighted photoacoustic signal (n = 9, P = 0.01) and increased oxyhemoglobin-weighted photoacoustic signal (n = 9, P < 0.01). The latter observation indicated normalization of the residual tumor vessels, which was also implied by low levels of angiopoietin 1 in serum biomarker profiling (0.76 ± 0.12 ng/mL). These noninvasive measures reflected a 30% reduction in microvessel density and increased vessel maturation in ex vivo sections. CONCLUSION: Photoacoustic tomography is able to evaluate both vessel regression and normalization in response to trebananib. Noninvasive imaging data were supported by modulation of serum markers in vitro and ex vivo histopathology.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Beth Y Karlan; Amit M Oza; Gary E Richardson; Diane M Provencher; Vincent L Hansen; Martin Buck; Setsuko K Chambers; Prafull Ghatage; Charles H Pippitt; John V Brown; Allan Covens; Raj V Nagarkar; Margaret Davy; Charles A Leath; Hoa Nguyen; Daniel E Stepan; David M Weinreich; Marjan Tassoudji; Yu-Nien Sun; Ignace B Vergote Journal: J Clin Oncol Date: 2011-12-19 Impact factor: 44.544
Authors: Eric E Nilsson; Suzanne D Westfall; Claudia McDonald; Tiffany Lison; Ingrid Sadler-Riggleman; Michael K Skinner Journal: Cancer Chemother Pharmacol Date: 2001-11-23 Impact factor: 3.333
Authors: Angela Coxon; James Bready; Hosung Min; Stephen Kaufman; Juan Leal; Dongyin Yu; Tani Ann Lee; Ji-Rong Sun; Juan Estrada; Brad Bolon; James McCabe; Ling Wang; Karen Rex; Sean Caenepeel; Paul Hughes; David Cordover; Haejin Kim; Seog Joon Han; Mark L Michaels; Eric Hsu; Grant Shimamoto; Russell Cattley; Eunju Hurh; Linh Nguyen; Shao Xiong Wang; Anthony Ndifor; Isaac J Hayward; Beverly L Falcón; Donald M McDonald; Luke Li; Tom Boone; Richard Kendall; Robert Radinsky; Jonathan D Oliner Journal: Mol Cancer Ther Date: 2010-10 Impact factor: 6.261
Authors: Roy S Herbst; David Hong; Linnea Chap; Razelle Kurzrock; Edward Jackson; Jeffrey M Silverman; Erik Rasmussen; Yu-Nien Sun; Don Zhong; Yuying C Hwang; Jeffrey L Evelhoch; Jonathan D Oliner; Ngocdiep Le; Lee S Rosen Journal: J Clin Oncol Date: 2009-06-22 Impact factor: 44.544
Authors: Lacey R McNally; Megan Mezera; Desiree E Morgan; Peter J Frederick; Eddy S Yang; Isam-Eldin Eltoum; William E Grizzle Journal: Clin Cancer Res Date: 2016-05-20 Impact factor: 12.531
Authors: Poorva Ghosh; Yihang Guo; Adnin Ashrafi; Jingyu Chen; Sanchareeka Dey; Shigen Zhong; Jie Liu; James Campbell; Purna Chaitanya Konduri; Jeni Gerberich; Massoud Garrossian; Ralph P Mason; Li Zhang; Li Liu Journal: Cancer Res Date: 2020-06-16 Impact factor: 12.701